Fusobacterium necrophorum Endocarditis with Liver Abscesses: A Case Report and Review of the Literature

Kaho Sato¹, Taku Matsubara¹, Shunsuke Imai¹, Katsuharu Hatada¹, Wataru Mitsuma¹, Satoshi Kawasaki², Isamu Hama³ and Takeshi Kamura⁴

Abstract:
Fusobacterium necrophorum is a very rare cause of endocarditis. We herein report a case of F. necrophorum endocarditis with liver abscesses in a 51-year-old woman. This is the first reported case of monomicrobial F. necrophorum endocarditis to present in a patient over 50 years old. We also reviewed 10 reported cases, including the present case. Our review indicated that anaerobic bacteria, including Gram-negative anaerobic bacilli such as F. necrophorum, should be considered in the differential diagnosis of infective endocarditis, especially in patients without preexisting organic heart disease.

Key words: infectious endocarditis, Fusobacterium necrophorum, liver abscess

(Intern Med 60: 2445-2449, 2021)  
(DOI: 10.2169/internalmedicine.6348-20)

Introduction

Fusobacterium spp. are obligate anaerobic Gram-negative bacilli that are rare causes of several severe diseases (1, 2). F. nucleatum is the most frequent causative species (61%) of Fusobacterium spp. bacteremia, followed by F. necrophorum (25%). F. necrophorum bacteremia typically occurs in younger populations without underlying comorbidities and is usually absent in patients over 40 years old (2).

Endocarditis due to anaerobic Gram-negative bacilli is relatively uncommon. We herein report the first case of F. necrophorum endocarditis in a patient over 50 years old and review 9 previously reported cases.

Case Report

A 51-year-old previously healthy woman presented to the emergency room complaining of a fever, weakness and chills. Her vital signs upon admission were as follows: temperature, 40.7 °C; blood pressure, 144/90 mmHg; and pulse rate, 110 beats/minute.

A physical examination showed no abnormalities in her heart or lungs. The abdomen was benign, the liver and spleen were not palpable, and the patient had no tenderness or skin lesions. Although the patient had severe dental and periodontal disease, no pharyngitis or jugular venous thrombophlebitis of the neck were evidenced.

Chest X-ray revealed no infiltrate or congestion. Laboratory tests showed leukocytes, 2,780/mm³; platelets, 142,000/mm³; urea nitrogen, 14 mg/dL; and creatinine, 0.77 mg/dL. Liver tests showed aspartate transaminase, 54 IU/L; alanine transaminase, 26 IU/L; lactate dehydrogenase, 254 IU/L; and total bilirubin, 0.6 mg/dL. Serologic studies showed that the patient’s C-reactive protein was 10.92 mg/dL, and her rheumatoid factor was 17.0 IU/mL (normal range 0-15.0 IU/mL). Other laboratory findings showed elevated levels of presepsin (584 pg/mL), a specific biomarker in patients with sepsis (normal range 0-313 pg/mL) as well as fibrinogen (563 mg/dL), fibrin degradation products (34.4 mg/L) and D-dimer (10.88 mg/L). Her urinalysis showed 4+ proteinuria and 10-19 red blood cells per high-power field. Two sets of both aerobic and anaerobic blood cultures were obtained from two different sites on the day of admission. Both anaerobic blood cultures grew Gram-negative bacilli within 48 hours; these bacilli were identified by day 6 as F. necropho-
rum. The aerobic blood cultures were sterile. The urine culture obtained on the day of admission was negative.

Initial computed tomography (CT) of the chest and abdomen performed without intravenous contrast showed two 1-cm hypodense lesions on the right hepatic lobe and diffuse swelling of both kidneys. Colonoscopy showed no abnormal findings. An ultrasound examination of the neck showed no evidence of thrombus of the bilateral neck veins. Transthoracic echocardiography revealed 6×7-mm vegetation on the anterior mitral leaflet and mild mitral valve regurgitation (Fig. 1). Repeated CT of the abdomen performed on day 4 of hospitalization showed 2 complex liver lesions enhanced with intravenous contrast, which were 1.4×1.2 cm in S7 and 1.8×1.9 cm in S8, suggesting abscesses. The enhanced lesion in S8 was accompanied by a nonenhanced area in a branch of the right hepatic vein, suggesting hepatic vein thrombus. CT showed no evidence of biliary tract infection (Fig. 2).

The patient was administered meropenem starting one day after obtaining the blood culture samples, but it caused drug eruption. Because the Gram-negative bacilli isolated from both blood culture sets were sensitive to meropenem and ceftriaxone (Table 1), the patient was intravenously administered ceftriaxone starting on day 4. Her temperature appeared to stabilize; however, this improvement was short-lived. Ten days later, she became febrile again (temperature, 39.4°C). Four more blood culture sets were obtained 9 and 14 days after admission (6 and 11 days after ceftriaxone administration) and were negative. Metronidazole was added to the ceftriaxone on day 16 after admission, and her fever decreased over the next 4 weeks. Metronidazole combined with ceftriaxone was continued for four weeks without side effects.

---

**Figure 1.** Transthoracic echocardiogram. Image shows 6×7-mm vegetation (arrowheads) on the anterior mitral leaflet.

**Figure 2.** Computed tomography scans of the abdomen demonstrating liver abscesses (red arrows) and hepatic vein thrombus (yellow arrows). A: arterial-dominant phase, B: equilibrium phase, C: portal-dominant phase.
Table 1. Minimum Inhibitory Concentrations (MICs).

| Antimicrobial agent     | MIC (mg/L) |
|-------------------------|------------|
| Benzylpenicillin        | ≤0.03      |
| Ampicillin              | ≤0.03      |
| Ampicillin/Sulbactam    | ≤0.25      |
| Piperacillin/Tazobactam | ≤0.16      |
| Cefoperazone/Sulbactam  | ≤0.08      |
| Cefazolin               | ≤0.5       |
| Ceftriaxone             | ≤0.06      |
| Cefazidime              | ≤1         |
| Cefepime                | ≤0.06      |
| Cefmetazole             | ≤1         |
| Flomoxef                | ≤1         |
| Imipenem/Cilastatin     | ≤0.06      |
| Meropenem               | ≤0.06      |
| Minocycline             | ≤0.12      |
| Clindamycin             | ≤0.12      |
| Levofloxacin            | 2          |
| Chloramphenicol         | 1          |
| Clarithromycin          | 8          |
| Azithromycin            | 1          |

Discussion

Anaerobic bacteria are uncommon causes of infective endocarditis (IE) (2-16%) (3). Anaerobic IE has been associated with a lower frequency of preexisting valvular heart disease than of endocarditis caused by aerobic bacteria (4). The echocardiographic results may be normal in up to half of all cases and therefore cannot be used to rule out an IE diagnosis (5). Anaerobic Gram-negative bacilli attack normal valves more often than do typical microorganisms that cause IE. Underlying cardiac disease is seen only in one-third of F. necrophorum endocarditis cases (4, 6, 7).

Major embolic phenomena are a prominent complication of endocarditis caused by anaerobic Gram-negative bacilli (3, 6). Septic embolization to distal sites, which can bring about “metastatic abscesses”, is common in patients with such endocarditis (8, 9). Lemierre’s syndrome, the usual etiologic agent of which is F. necrophorum, involves septic thrombophlebitis of the internal jugular vein, usually secondary to an acute oropharyngeal infection, and is frequently complicated by metastatic abscesses. Although the lung is the most common metastatic target, other reported

Table 2. Published Data on Patients with Monomicrobial Fusobacterium necrophorum Endocarditis.

| Case No | References | Reported year | Age/sex | Presumed infection source | Prior cardiac abnormalities | Valve involved | Complications | Treatment/outcome |
|---------|------------|---------------|---------|--------------------------|-----------------------------|----------------|---------------|------------------|
| 1       | 16         | 1983          | 16/F    | URTI                     | Not stated                  | Vegetation on prolapsed mitral valve | Meningitis with 12th cranial nerve paresis and sphenoidal sinusitis | Penicillin and metronidazole/survived |
| 2       | 17         | 1992          | 2/M     | Pneumonia                | None                        | Severe MR       | Pneumoneumothorax, chest wall abscess and CHF | Vancomycin, cefazidime and metronidazole/survived after MVR |
| 3       | 5          | 1992          | 2/M     | Pneumonia                | None                        | Severe MR due to chordal rupture | Pneumoneumothorax, lung abscesses | Vancomycin, cefazidime and metronidazole/survived after MVR |
| 4       | 18         | 2007          | 20/M    | Enteritis                | None                        | Vegetation on aortic valve, mild AR | None | Penicillin/survived |
| 5       | 19         | 2010          | 20/F    | URTI                     | Unable to identify          | Vegetation on mitral valve, severe MR | Pneumoneumothorax | Cefotaxim and levofloxacin/died after MVR |
| 6       | 20         | 2011          | 25/M    | Pharyngitis              | None                        | Vegetation on tricuspid valve | Lung abscesses, abscess in gluteal region with myositis and fasciitis, facial vein thrombosis | Clindamycin and penicillin/survived |
| 7       | 9          | 2011          | 25/M    | URTI                     | Bicuspid aortic valve       | Vegetation on aortic valve, severe AR | Liver and splenic abscesses | Piperacillin/tazobactam/survived after AVR |
| 8       | 15         | 2013          | 34/M    | Dental procedure         | None                        | Vegetation on mitral valve | Cerebral infarction and acute respiratory distress syndrome | Vancomycin, ceftriaxone and metronidazole/died |
| 9       | 21         | 2020          | 49/M    | Unable to identify       | None                        | Vegetation on aortic valve, no AR | Lung and liver abscesses and kidney infarction | Piperacillin/tazobactam/survived |

Our case | 51/F | Dental and periodontal disease | None | Vegetation on mitral valve, mild MR | Liver abscesses | Ceftriaxone and metronidazole/survived |

M: male, F: female, URTI: upper respiratory tract infection, MR: mitral regurgitation, CHF: congestive heart failure, MVR: mitral valve replacement, AR: aortic regurgitation, AVR: aortic valve replacement
sites of disseminated septic embolism include the systemic joints, muscles, kidneys, liver and spleen associated with abscesses (9, 10). *F. necrophorum* can produce endotoxins and leukotoxins and affect platelet aggregation, which is thought to cause the distinguishing clinical features (11, 12). Our patient had a severe dental infection and liver abscesses accompanied by hepatic vein thrombus. Because the liver abscesses may have been associated with biliary tract infection or a rectal lesion, CT and colonoscopy were performed but showed no evidence of the source of the patient’s bacteremia. Brain CT and magnetic resonance imaging had not been performed, as the physical examination showed no abnormality in neurological findings.

Historically, *F. necrophorum* has more than 50 synonyms owing to inadequate reporting of microbiological details and confusion pertaining to the nomenclature in earlier eras (13, 14). Unsophisticated anaerobic culturing methods are thought to have led to the misattribution of a causal role to organisms such as streptococci. Thus, *F. necrophorum* was not always reliably identified in cases reported before 1950 (14, 15). Table 2 summarizes the clinical features and hospital courses of previously published cases of monomicrobial *F. necrophorum* endocarditis as well as those of our case. Some cases in which a monomicrobial infection could not be confirmed were excluded from Table 2. To our knowledge, nine cases other than our own have been reported since 1980 (5, 9, 15-21). Six of these patients had no history of valvular heart disease. Metastatic abscesses were reported since 1980 (5, 9, 15-21). Six of these patients had no knowledge, nine cases other than our own have been reported.

**Conclusion**

We treated a 51-year-old patient with *F. necrophorum* endocarditis. In the differential diagnosis of IE in patients without preexisting valvular heart disease, anaerobic bacteria, including Gram-negative anaerobic bacilli such as *F. necrophorum*, should be considered as possible causative organisms, regardless of the patient’s age.

**The authors state that they have no Conflict of Interest (COI).**

**Acknowledgement**

We thank Yasuo Honma for his technical assistance.

**References**

1. Huggan PJ, Murdoch DR. Fusobacterial infections: clinical spectrum and incidence of invasive disease. *J Infect* 57: 283-289, 2013.
2. Afra K, Laupland K, Leal J, Lloyd T, Gregson D. Incidence, risk factors, and outcomes of *Fusobacterium* species bacteremia. *BMC Infect Dis* 13: 264-269, 2013.
3. Brook I. Infective endocarditis caused by anaerobic bacteria. Arch Cardiovasc Dis 101: 665-676, 2008.
4. Brook I. Endocarditis due to anaerobic bacteria. *Cardiology* 98: 1-5, 2002.
5. Stuart G, Wren C. Endocarditis with acute mitral regurgitation caused by *Fusobacterium necrophorum*. *Pediatr Cardiol* 13: 230-232, 1992.
6. Nastro LJ, Finegold SM. Endocarditis due to anaerobic Gram-negative bacilli. *Am J Med* 54: 482-496, 1973.
7. Felner JM, Dowell VR Jr. Anaerobic bacterial endocarditis. *N Engl J Med* 283: 1188-1192, 1970.
8. Moore-Gillon J, Lee TH, Ekyyn SJ, Phillips I. Necrobacillosis: a forgotten disease. *Br Med J* 288: 1526-1527, 1984.
9. Handler MZ, Mirivosky B, Gendelman HE, Sandikovsky U. *Fusobacterium necrophorum* causing infective endocarditis and liver and splenic abscesses. Rev Inst Med Trop Sao Paolo 53: 169-172, 2011.
10. Chirinos JA, Lichtstein DM, Garcia J, Tamariz LJ. The evolution of Lemierre syndrome. *Medicine* 81: 458-465, 2002.
11. Forrester LJ, Campbell BJ, Berg JN, Barrett JT. Aggregation of platelets by *Fusobacterium necrophorum*. *J Clin Microbiol* 22: 245-249, 1985.
12. Tan ZL, Nagaraja TG, Chengappa MM. *Fusobacterium necrophorum* infections: virulence factors, pathogenic mechanism and control measures. *Veterinary Res Comm* 20: 113-140, 1996.
13. Finegold SM. Problems in classification and characterization. *Anaerobic Bacteria in Human Disease*. Academic Press, New York, 1977: 9-26.
14. Riordan T. Human infection with *Fusobacterium necrophorum* (Necrobacillosis), with a focus on Lemierre’s syndrome. *Clin Microbiol Rev* 20: 622-659, 2007.
15. Moore C, Addison D, Wilson JM, Zehuff B. First case of *Fusobacterium necrophorum* endocarditis to have presented after the 2nd decade of life. *Tex Heart Inst J* 40: 449-452, 2013.
16. Adams J, Capistrant T, Crossley K, Johanssen R, Liston S. *Fusobacterium necrophorum* septicemia. *JAMA* 250: 35, 1983.
17. Epstein M, Pearson ADJ, Hudson SJ, Bray R, Taylor M, Beesley J. Necrobacillosis with pancytopenia. *Arch Dis Child* 67: 958-959, 1992.
18. Vedire S, Alpert MA, Ren J, Manian FA. *Fusobacterium necrophorum* endocarditis in a previously healthy young adult. *Am J Med Sci* 334: 125-127, 2007.
19. Augusto JF, Mercat A, Asfer P, Pinaud F, Croute A, Chausseret L. Fatal case of *Fusobacterium necrophorum* mitral endocarditis. *J Infect* **61**: 94-95, 2010.
20. Samant JS, Peacock JE Jr. *Fusobacterium necrophorum* endocarditis. Case report and review of the literature. *Diagn Microbiol Infect Dis* **69**: 192-195, 2011.
21. Volpe N, Connolly S, Cheema B, Angarone M. A curious case of endocarditis and liver abscess in a previously healthy man. *Am J Med* **133**: 186-190, 2020.
22. Kuppalli K, Livorsi D, Talati N, Osborn M. Lemierre’s syndrome due to *Fusobacterium necrophorum*. *Lancet Infect Dis* **12**: 808-815, 2012.
23. Chukwu EE, Nwaokorie FO, Coker AO. A review of *Fusobacterium necrophorum* infections in humans. *Br Microbiol Res J* **4**: 480-496, 2014.
24. Appelbaum PC, Spangler SK, Jacobs MR. Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-*Bacteroides fragilis* Bacteroides isolates and 129 Fusobacteria from 28 U.S. Centers. *Antimicrob Agents Chemother* **34**: 1546-1550, 1990.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).